139 related articles for article (PubMed ID: 15264245)
1. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
Ziada A; Barqawi A; Glode LM; Varella-Garcia M; Crighton F; Majeski S; Rosenblum M; Kane M; Chen L; Crawford ED
Prostate; 2004 Sep; 60(4):332-7. PubMed ID: 15264245
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
3. HER-2 profiling and targeting in prostate carcinoma.
Morris MJ; Reuter VE; Kelly WK; Slovin SF; Kenneson K; Verbel D; Osman I; Scher HI
Cancer; 2002 Feb; 94(4):980-6. PubMed ID: 11920466
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
Baselga J; Carbonell X; Castañeda-Soto NJ; Clemens M; Green M; Harvey V; Morales S; Barton C; Ghahramani P
J Clin Oncol; 2005 Apr; 23(10):2162-71. PubMed ID: 15800309
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Dang CT; Dannenberg AJ; Subbaramaiah K; Dickler MN; Moasser MM; Seidman AD; D'Andrea GM; Theodoulou M; Panageas KS; Norton L; Hudis CA
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4062-7. PubMed ID: 15217939
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
12. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
15. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
16. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
17. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
Formento P; Hannoun-Levi JM; Fischel JL; Magné N; Etienne-Grimaldi MC; Milano G
Eur J Cancer; 2004 Dec; 40(18):2837-44. PubMed ID: 15571968
[TBL] [Abstract][Full Text] [Related]
18. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
Mohsin SK; Weiss HL; Gutierrez MC; Chamness GC; Schiff R; Digiovanna MP; Wang CX; Hilsenbeck SG; Osborne CK; Allred DC; Elledge R; Chang JC
J Clin Oncol; 2005 Apr; 23(11):2460-8. PubMed ID: 15710948
[TBL] [Abstract][Full Text] [Related]
20. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
